Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: A retrospective study

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 4, 2002, Pages 309-321

  Sládek, Norman E ^a   Kollander, Rahn ^a   Sreerama, Lakshmaiah ^a   Kiang, David T ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Cancer chemotherapy; Drug metabolism; Drug resistance; Oxazaphosphorine

Indexed keywords

ALDEHYDE DEHYDROGENASE; CYCLOPHOSPHAMIDE; IFOSFAMIDE; OXAZAPHOSPHORINE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER SIZE; CATALYSIS; CELL LEVEL; CELL SURVIVAL; CONTROLLED STUDY; DRUG DETOXIFICATION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL RECORD; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; ALDEHYDE DEHYDROGENASE; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; ISOENZYMES; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 0036202207     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-001-0412-4     Document Type: Article

References (43)

1. The role of DNA damage in the resistance of human chronic myeloid leukemia cells to cyclophosphamide analogues
2. Clinically-relevant cyclophosphamide analog resistance can be induced by single drug exposure in human leukemic cells
3. Adjuvant systemic therapy in women with early-stage breast cancer at high risk for relapse
4. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde
5. Relative contribution of human erythrocyte aldehyde dehydrogenase to the systemic detoxification of the oxazaphosphorines
6. Mechanisms of resistance to the toxicity of cyclophosphamide
7. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer
8. The early stages of absorption of injected horseradish peroxidase in the proximal tubules of mouse kidney: Ultrastructural cytochemistry by a new technique
9. Adjuvant systemic therapy of early breast cancer
10. Chemotherapy for metastatic disease
11. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies
12. Cyclophosphamide, methotrexate, and fluorouracil: Still the gold standard?
13. High-dose chemotherapy with reinfusion of purged autologous bone marrow following doseintense induction as initial therapy for metastatic breast cancer
14. Combination therapy of hormone and cytotoxic agents in advanced beast cancer
15. Changes in the patterns of aldehyde dehydrogenase activity in primary and metastatic adenocarcinomas of the human colon
16. Role of aldehyde dehydrogenase in the protection of hematopoietic progenitor cells from 4-hydroperoxycyclophosphamide by interleukin 1β and tumor necrosis factor
17. Interleukin-1 and tumor necrosis factor alpha induce class 1 aldehyde dehydrogenase mRNA and protein in bone marrow cells
18. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: Effect of ex vivo purging with 4-hydroperoxycyclophosphamide
19. Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol
20. Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase
21. Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by chlorpropamide analogues
22. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: A phase I trial
23. Oxazaphosphorine-specific acquired cellular resistance
24. Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines
25. Aldehyde dehydrogenase-mediated relative insensitivity to the oxazaphosphorines
26. Leukemic cell insensitivity to cyclophosphamide and other oxazaphosphorines mediated by aldehyde dehydrogenase(s)
27. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines
28. Collateral sensitivity to cross-linking agents exhibited by cultured L1210 cells resistant to oxazaphosphorines
29. Constitutive and overexpressed human cytosolic class-3 aldehyde dehydrogenases in normal and neoplastic cells/secretions
30. Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance
31. Overexpression or polycyclic aromatic hydrocarbon-mediated induction of an apparently novel class 3 aldehyde dehydrogenase in human breast adenocarcinoma cells and its relationship to oxazaphosphorinespecific acquired resistance
32. Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance
33. Over-expression of glutathione S-transferases, DT-diaphorase and an apparently tumorspecific cytosolic class-3 aldehyde dehydrogenase by Warthin tumors and mucoepidermoid carcinomas of the human parotid gland
34. Cellular levels of class 1 and class 3 aldehyde dehydrogenases and certain other drug metabolizing enzymes in human breast malignancies
35. Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents
36. Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants
37. Identification of a class 3 aldehyde dehydrogenase in human saliva and increased levels of this enzyme, glutathione S-transferases, and DT-diaphorase in the saliva of subjects who continually ingest large quantities of coffee or broccoli
38. Phenolic antioxidant-induced overexpression of class-3 aldehyde dehydrogenase and oxazaphosphorine-specific resistance
39. High-dose chemotherapy for breast cancer
40. Eukaryotic aldehyde dehydrogenase (ALDH) genes: Human polymorphisms, and recommended nomenclature based on divergent evolution and chromosomal mapping
41. Aldehyde dehydrogenase isoenzymes in tumours - Assay with possible prognostic value for oxazaphosphorine chemotherapy
42. Genetic polymorphism and activities of human lung alcohol and aldehyde dehydrogenases: Implications for ethanol metabolism and cytotoxicity
43. Much ado about not...enough data: High-dose chemotherapy with autologous stem cell rescue for breast cancer